Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system

Lee, Sung Eun; Lee, Chan Mi; Won, Ji; Jang, Gun-Young; Lee, Ju Hyeong; Park, Sang Hyeon; Kang, Tae Heung; Han, Hee Dong; Park, Yeong‐Min

doi:10.1016/j.biomaterials.2022.121677

Cited by 8 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Park et al developed annexin A5-labeled NPs (AnnV_PLGA_NPs) as the inhibitor to this innate immune checkpoint. Mutant neoantigen peptides (Nbea, PAPRAVLT GHDHEIVCVSVCAELGLVI) were loaded in NPs (AnnV_PLGA (Nbea)_NPs) to elicit antigen-specific antitumor immunity (119). In company with cisplatin (Cis)-mediated chemotherapy, AnnV_PLGA(Nbea)_NPs spurred the infiltration of immuneactivate cells and the secretion of pro-inflammatory cytokines, while depleting immune-suppressive MDSCs and Tregs and decreased the production of anti-inflammatory cytokines at the same time.…”

Section: Ps Externalizationmentioning

confidence: 99%

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Liu

Xiang²,

Zheng³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) has gained unparalleled success in the treatment of colorectal cancer (CRC). However, undesired side effects, unsatisfactory response rates, tumor metastasis, and drug resistance still hinder the further application of ICB therapy against CRC. Advancing ICB with nanotechnology can be game-changing. With the development of immuno-oncology and nanomaterials, various nanoplatforms have been fabricated to enhance the efficacy of ICB in CRC treatment. Herein, this review systematically summarizes these recent nano-strategies according to their mechanisms. Despite their diverse and complex designs, these nanoplatforms have four main mechanisms in enhancing ICB: 1) targeting immune checkpoint inhibitors (ICIs) to tumor foci, 2) increasing tumor immunogenicity, 3) remodeling tumor microenvironment, and 4) pre-sensitizing immune systems. Importantly, advantages of nanotechnology in CRC, such as innovating the mode-of-actions of ICB, modulating intestinal microbiome, and integrating the whole process of antigen presentation, are highlighted in this review. In general, this review describes the latest applications of nanotechnology for CRC immunotherapy, and may shed light on the future design of ICB platforms.

show abstract

Section: Ps Externalizationmentioning

confidence: 99%

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Liu

Xiang²,

Zheng³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Sung Eun Lee et al designed and developed a selective nanocarrier system which was consisted of membrane-linked protein A5-tagged PLGA-NPs. Then, the membrane-linked protein A5-tagged PLGA-NPs was encapsulated with tumor-specific antigens to stimulate anti-tumor immune response by increase the level of IFN-γ and CD8 + T cells [ 150 ]. Piyush Kumar and Rohit Srivastava prepared a novel PCL glycol chitosan (GC)-polysaccharide co-blended nanoparticles (PP-IR-NP) encapsulated with highly biocompatible and biodegradable monodisperse IR 820 for imaging purposes and effective PTT.…”

Section: Tumor Immunotherapy Based On Organic Nanomaterialsmentioning

confidence: 99%

Nanomaterials in tumor immunotherapy: new strategies and challenges

Zhu

2023

Mol Cancer

View full text Add to dashboard Cite

Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.

show abstract

“…Annexin A5(ANXA5) is a member of the annexin family of proteins and is well-known for its ability to bind to anionic phospholipids in a Ca 2+ - dependent manner 5 . ANXA5 displays several activities including cell membrane repair 6 , anti-coagulation 7 , anti-inflammatory 6 , and immunomodulatory effects 8 . Cancer biology is another area of ANXA5 activity that has been the focus of numerous researches in recent decades 9 .…”

Section: Introductionmentioning

confidence: 99%

Annexin-A5 Overexpression Increases Sensitivity of MCF-7 and MCF-7/ADR Cells to Epirubicin

Ghasemi,

Reiazi,

Behzad-Behbahani

et al. 2023

AJMB

View full text Add to dashboard Cite

Background: Multi-drug resistance is an important challenge in the chemotherapy of cancer. The role of annexin A5 (ANXA5) in the biology of cancer has been the focus of many studies. Breast Cancer (BC) is frequent cancer in women with high morbidity and mortality rate. The present study aimed to investigate the effects of ANXA5 overexpression on the anti-tumor activity of Epirubicin (EPI) in MCF-7 and MCF-7/ADR cells. Methods: MCF-7 and MCF-7/ADR cells were transfected with the pAdenoVator-CMV-ANXA5-IRES-GFP plasmid or mock plasmid. The overexpression of ANXA5 was evaluated using qPCR. The effects of ANXA5 overexpression and EPI on the cell viability of MCF-7 and MCF-7/ADR cells were measured using an MTT assay. Cell apoptosis was measured by annexin V/7-AAD flow cytometry assay. Results: Following the overexpression of ANXA5, the viability of MCF-7 and MCF-7/ADR was significantly decreased. Furthermore, the overexpression of ANXA5 in MCF-7 cells increased the cytotoxic effects of EPI in all doses and reduced the IC50 of EPI from 17.69 µM to 4.07 µM. Similarly, the overexpression of ANXA5 in MCF7-ADR cells reduced the IC50 of EPI from 27.3 µM to 6.69 µM. ANXA5 overexpression alone or combined with EPI treatment increased the apoptosis of MCF7 and MCF7-ADR cells. Conclusion: The results of the present study demonstrate that ANXA5 overexpression increases the sensitivity of MCF-7 and MCF-7/ADR to EPI, suggesting a possible beneficial role of ANXA5 in the therapy of BC.

show abstract

Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system

Cited by 8 publications

References 41 publications

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Nanomaterials in tumor immunotherapy: new strategies and challenges

Annexin-A5 Overexpression Increases Sensitivity of MCF-7 and MCF-7/ADR Cells to Epirubicin

Contact Info

Product

Resources

About